StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

Browse signals
APYXBullishIndustry Newsnews
High materiality8/10

Apyx Clinical Data Shows Elastin Gains and Inflammation Reduction from Renuvion

Sep 29, 2026, 8:18 AM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting

Positive biomarker data and 100% reported improvements could boost physician demand and AYON-related revenue, though small sample size tempers confidence.

AI summary

What happened, with direct paths to the underlying reporting

APYX announced day-180 results from a prospective study using Renuvion helium plasma RF on skin quality markers. Treated tissue showed 30% elastin density gain, 55% higher elastin staining, and 34% inflammation reduction, with 100% reporting aesthetic improvement and satisfaction. The small, post-market study supports a biological basis for observed skin benefits and AYON integration.

  • Day-180 study shows elastin increase and inflammation reduction with Renuvion.
  • Elastin density up 30%; elastin staining up 55%.
  • 100% reported aesthetic improvement and satisfaction.
  • Small, post-market study; n=6 across two sites.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Related signals

More source-backed signals connected by company or event